Results 161 to 170 of about 43,067 (192)

Association of HLA-B*53 With DRESS Syndrome in Patients Treated With Raltegravir: Two Case Reports and a Literature Review. [PDF]

Basic Clin Pharmacol Toxicol
Ramos-Del Moral C, Rodríguez Cortés P, Navares-Gómez M, Campodónico D, Almenara de Riquer S, Barrios Blandino A, Mejía-Abril G, Gómez-Fernández A, Romero Sastre O, Carles García P, Abad-Santos F.   +10 more
europepmc   +1 more source

HIV drug resistance in children and adolescents on NNRTI-based antiretroviral therapy and subsequent virologic response to dolutegravir-based regimens in Ghana. [PDF]

AIDS Res Ther
Afrane AKA, Novitsky V, Hague J, Sagoe K, Alhassan Y, Dame JA, Martyn-Dickens C, Lartey M, Goka B, Torpey K, Kantor R, Kwara A.   +11 more
europepmc   +1 more source

A preliminary survey on the use of ART among blood donors in Shenzhen China and its implications to blood safety. [PDF]

BMC Infect Dis
Wang L, Xie H, Zhao F, Zhang L, Yang Z, Liu Y, Li T, Chen T, Xu X, Dang Y, Zhang Q, Wang Z, Wei G, Sun J, Xi J, Xi C, Zeng J, Xia R, Chen L.   +18 more
europepmc   +1 more source

Third-Trimester HIV Viremia Treated With Long-Acting Cabotegravir and Rilpivirine: A Case Report. [PDF]

Open Forum Infect Dis
Kazanji N, Max B, Burgos RM, Pham JT, Ford CE.   +4 more
europepmc   +1 more source

CD14^- CD16⁺ monocyte PD-L1 prevents early tuberculosis progression and constrains reactivation under immune checkpoint therapy. [PDF]

Front Cell Infect Microbiol
Wang W, Liu C, Wu W, Yi Z, Shen J.
europepmc   +1 more source

Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis.

Lancet Glob Health
Brenner IR, Flanagan CF, Penazzato M, Webb KA, Horsfall SB, Hyle EP, Abrams E, Bacha J, Neilan AM, Collins IJ, Desmonde S, Crichton S, Davies MA, Freedberg KA, Ciaranello AL.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Zidovudine Intolerance

Clinical Infectious Diseases, 1990
Patients may be intolerant of zidovudine for several reasons, the most prominent being hematologic toxicity. In vitro studies demonstrate that zidovudine is toxic to the myeloid and erythroid precursors in the bone marrow; at concentrations of zidovudine near those associated with the optimal antiviral effect in vitro, the proliferative capability of ...
openaire   +2 more sources

Zidovudine: Anno 1995

1996
In early 1987 treatment of symptomatic HIV-infected patients was improved by the availability and licensing of the nucleoside analogue zidovudine (ZDV, AZT, Retrovir®) as the first anti-retroviral drug in most countries of the developed world. Although more compounds have become available since then, zidovudine remains a cornerstone of therapy for HIV ...
openaire   +4 more sources

Zidovudine

Reactions, 1989
  +6 more sources

Zidovudine

The Lancet, 1992
  +5 more sources